See more : Unisync Corp. (UNI.TO) Income Statement Analysis – Financial Results
Complete financial analysis of CeriBell, Inc. (CBLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CeriBell, Inc., a leading company in the Healthcare industry within the Healthcare sector.
You may be interested
- Value Grupo Financiero, S.A.B. de C.V. (VALUEGFO.MX) Income Statement Analysis – Financial Results
- Oxford Biomedica plc (OXB.L) Income Statement Analysis – Financial Results
- Digital Brands Group, Inc. (DBGIW) Income Statement Analysis – Financial Results
- Auto Partner SA (APR.WA) Income Statement Analysis – Financial Results
- Atlinks Group Limited (8043.HK) Income Statement Analysis – Financial Results
CeriBell, Inc. (CBLL)
About CeriBell, Inc.
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 45.23M | 25.92M |
| Cost of Revenue | 7.06M | 4.43M |
| Gross Profit | 38.16M | 21.49M |
| Gross Profit Ratio | 84.38% | 82.91% |
| Research & Development | 9.00M | 7.24M |
| General & Administrative | 20.29M | 18.46M |
| Selling & Marketing | 38.92M | 31.81M |
| SG&A | 59.21M | 50.27M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 68.20M | 57.51M |
| Cost & Expenses | 75.27M | 61.94M |
| Interest Income | 0.00 | 0.00 |
| Interest Expense | 2.10M | 1.60M |
| Depreciation & Amortization | 847.00K | 497.00K |
| EBITDA | -26.51M | -35.06M |
| EBITDA Ratio | -58.61% | -135.26% |
| Operating Income | -30.04M | -36.02M |
| Operating Income Ratio | -66.43% | -138.96% |
| Total Other Income/Expenses | 588.00K | -1.14M |
| Income Before Tax | -29.45M | -37.16M |
| Income Before Tax Ratio | -65.13% | -143.36% |
| Income Tax Expense | 11.00K | 2.00K |
| Net Income | -29.46M | -37.16M |
| Net Income Ratio | -65.15% | -143.37% |
| EPS | -1.27 | -1.59 |
| EPS Diluted | -1.27 | -1.59 |
| Weighted Avg Shares Out | 23.12M | 23.32M |
| Weighted Avg Shares Out (Dil) | 23.12M | 23.32M |
CeriBell: Healthcare Technology Stock With A Promising Growth Outlook
Initiating coverage on CeriBell with a "Buy" rating, citing a promising growth outlook and a 24-month investment horizon. CeriBell's Ceribell System, an AI-powered EEG platform, shows strong revenue growth and high gross margins, indicating robust cash flow potential. The company...
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a...
Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024
SUNNYVALE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Ceribell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the...
CeriBell: An Interesting EEG Play Going Public
CeriBell's IPO was highly successful, with shares rising 60%, but I'm cautious about investing after such a significant price increase. The company offers a revolutionary EEG platform for neurological conditions, showing strong growth while still incurring substantial losses. Despite impressive...
New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG
—Five abstracts presented at the 2024 Neurocritical Care Society Annual Meeting demonstrated the clinical impact of the FDA-cleared Ceribell System and Ceribell's AI-powered Clarity™ algorithm— —Clarity remains first and only device FDA 510(k) cleared for the diagnosis of electrographic status...
CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SUNNYVALE, Calif. , Oct. 15, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the closing of its upsized initial public...
CeriBell IPO: Stock price will be closely watched today as the AI brain-monitoring headband maker debuts on the Nasdaq
CeriBell, a neurodiagnostic startup known for its brain-monitoring headband that can detect seizure activity, is making its market debut on Friday in an IPO that is expected to generate $180.3 million in proceeds. Here's what to know about the medtech...
Ceribell's stock indicates up 35% in trading debut after pricing IPO at top of range
Ceribell Inc., a medical-device maker that uses artificial intelligence to monitor patient seizures, was on track for a strong trading debut Friday, after its initial public offering priced at the top of its proposed range.
CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering
SUNNYVALE, Calif. , Oct. 10, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the pricing of its upsized initial public...
Source: https://incomestatements.info
Category: Stock Reports